Novartis India (NSE:NOVARTIND) Moat Score: 0/10 (As of Jul. 12, 2026)


NSE:NOVARTIND Novartis India Ltd NSE:NOVARTIND
62 GF Score
Price ₹1,494.60
GF Value ₹642.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Moat Score?

Novartis India has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Novartis India has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Novartis India might have No Moat - No discernible moat.

Novartis India  (NSE:NOVARTIND) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Novartis India Moat Score Related Terms

NSE:NOVARTIND
62GF Score
Novartis India Ltd NSE:NOVARTIND
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,494.60 is trading 132.7% above its estimated GF Value™ of ₹642.38. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for NSE:NOVARTIND:

  • Moat Score: 0
  • GF Value™: ₹642.38 vs. price of ₹1,494.60 (132.7% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis India Business Description

Other Exchanges 500672:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
62GF Score

Get the complete analysis for NSE:NOVARTIND

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,494.60
Price
₹642.38
GF Value